Insider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of Stock

Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 13,410 shares of the company’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $1.20, for a total value of $16,092.00. Following the transaction, the insider now directly owns 84,779 shares in the company, valued at $101,734.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Alimera Sciences, Inc. (NASDAQ ALIM) traded down $0.04 during mid-day trading on Friday, hitting $1.20. The stock had a trading volume of 329,291 shares, compared to its average volume of 180,769. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84. Alimera Sciences, Inc. has a 1-year low of $1.11 and a 1-year high of $1.72. The firm has a market capitalization of $82.98, a P/E ratio of -3.87 and a beta of 2.15.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. sell-side analysts forecast that Alimera Sciences, Inc. will post -0.27 earnings per share for the current year.

An institutional investor recently raised its position in Alimera Sciences stock. Stonepine Capital Management LLC lifted its position in Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 477,226 shares of the biopharmaceutical company’s stock after acquiring an additional 292,399 shares during the period. Alimera Sciences accounts for approximately 0.4% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned about 0.69% of Alimera Sciences worth $644,000 at the end of the most recent reporting period. Institutional investors own 41.78% of the company’s stock.

A number of equities analysts have recently issued reports on ALIM shares. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a research report on Wednesday, November 22nd. Cowen reaffirmed a “buy” rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. Finally, ValuEngine downgraded Alimera Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Alimera Sciences currently has an average rating of “Hold” and a consensus price target of $3.38.

WARNING: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.

Leave a Reply